Net Loss per Share

3 Months Ended

Mar. 31, 2025

9. Net Loss per Share

Basic and diluted net loss per common share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):


	Three Months Ended March 31,
	2025			2024
Numerator:
Net loss attributable to common stockholders	$	(22,413	)	$	(19,940	)
Denominator:
Weighted-average common shares outstanding, basic and diluted		46,067,878			39,864,111
Net loss per share attributable to common stockholders, basic and diluted	$	(0.49	)	$	(0.50	)

Basic and diluted weighted average shares of common stock outstanding for the three months ended March 31, 2025 and March 31, 2024 include the weighted average effect of outstanding pre-funded warrants for the purchase of shares of common stock for which the remaining unfunded exercise price is $0.0001 or less per share.

The Company’s potentially dilutive securities have been excluded from the computation of diluted net loss per common share as the effect would be to reduce the net loss per common share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per common share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per common share for the periods indicated because including them would have had an anti-dilutive effect:


	As of March 31,
	2025		2024
Series A convertible preferred stock		5,376,340		—
Options to purchase common stock – service based		9,262,778		7,802,988
Options to purchase common stock – performance based		210,629		210,629
Unvested restricted common stock		—		9,768
Total		14,849,747		8,023,385

Vigil Neuroscience, Inc. 10-Q